Univest
Univest
  • Markets

3 Home Care and Textile Chemicals Maker, Multi Speciality Hospitals Group and Data Analytics Company Stocks With a Strong Future Roadmap: Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics

  • November 17, 2026
  • Posted by: Ankit Jaiswal
  • Category: Best Stocks
No Comments
3 Home Care and Textile Chemicals Maker, Multi Speciality Hospitals Group and Data Analytics Company Stocks With a Strong Future Roadmap: Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics

Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics: ROE of 10.8% to 17.8% and FY22 to FY26 revenue CAGR of 12.8% to 27.6%. Prices as of 16 Nov 2026.

Quick Answer

The three biotech chemical, heart care and data stocks to watch are Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics. Their return on equity ranges from 10.8% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.8% to 27.6%. Narayana Hrudayalaya has the highest return on equity at 17.8%, while Latent View Analytics has the fastest revenue growth at 27.6% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Biotech chemical, heart care and data stocks give investors a way to track businesses that sit close to everyday demand in India. Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics cover a home care and textile chemicals maker, a multi speciality hospitals group and a data analytics company.

This list covers three biotech chemical, heart care and data stocks with complete current figures: Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Are Biotech Chemical, Heart Care and Data Stocks?
  • Biotech Chemical, Heart Care and Data Stocks at a Glance
  • Why Do Biotech Chemical, Heart Care and Data Stocks Have a Strong Roadmap in India?
  • Why Rossari Biotech Features Among These Biotech Chemical, Heart Care and Data Stocks
  • Why Narayana Hrudayalaya Features Among These Biotech Chemical, Heart Care and Data Stocks
  • Why Latent View Analytics Features Among These Biotech Chemical, Heart Care and Data Stocks
  • Rossari Biotech vs Narayana Hrudayalaya vs Latent View Analytics on Key Financials
  • Key Risks to Check Before Investing in Biotech Chemical, Heart Care and Data Stocks
  • Final Thoughts on Biotech Chemical, Heart Care and Data Stocks
    • What are biotech chemical, heart care and data stocks?
    • Which biotech chemical, heart care and data stocks are covered in this list?
    • Why do biotech chemical, heart care and data stocks have a strong future roadmap in India?
    • How has Rossari Biotech performed financially?
    • How has Narayana Hrudayalaya performed financially?
    • How has Latent View Analytics performed financially?
    • What risks should investors check before buying biotech chemical, heart care and data stocks?
    • Is this list of biotech chemical, heart care and data stocks investment advice?

What Are Biotech Chemical, Heart Care and Data Stocks?

Biotech chemical, heart care and data stocks are listed companies that make specialty chemicals for home care, textiles and animal care, run multi speciality hospitals with a focus on heart care, and provide data analytics services to global clients. Their earnings depend on chemical demand, patient volumes and client technology budgets.

Biotech Chemical, Heart Care and Data Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Rossari Biotech 427.15 2,363 15.5 33.9 10.8 0.28
Narayana Hrudayalaya 1,895.3 35,603 43.6 59.6 17.8 1.29
Latent View Analytics 201.51 4,968 25.0 17.5 11.3 0.02

On valuation, Rossari Biotech and Narayana Hrudayalaya trade at a P/E below the industry P/E, while Latent View Analytics trades above it, which reflects the growth the market already expects. Readers comparing biotech chemical, heart care and data stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Biotech Chemical, Heart Care and Data Stocks Have a Strong Roadmap in India?

Biotech chemical, heart care and data stocks have a strong roadmap in India because wider use of specialty chemicals, rising need for affordable specialist care and growing use of data in business decisions keep widening the market for these companies.

  • Specialty chemicals. Brands need niche formulation inputs.
  • Heart hospitals. Families seek affordable specialist care.
  • Data analytics. Firms use data to decide faster.

Why Rossari Biotech Features Among These Biotech Chemical, Heart Care and Data Stocks

Among the biotech chemical, heart care and data stocks on this list, Rossari Biotech makes specialty chemicals for home, personal and performance applications, including textile chemicals, animal health and nutrition products and ingredients for fast-moving consumer goods.

Revenue rose from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew from Rs 97.7 crore in FY22 to Rs 149 crore in FY26, which works out to a compound annual growth rate of 11.2%.

The company has a return on equity of 10.8%, a debt to equity ratio of 0.28 and a market capitalisation of Rs 2,363 crore. The stock trades at a P/E of 15.5, below the industry P/E of 33.9.

Roadmap: The company is broadening its range across home and personal care, animal nutrition and performance chemicals. Cross-selling to existing customers helps add volume.

What to watch: Track new product additions, customer wins and margin trends.

Why Narayana Hrudayalaya Features Among These Biotech Chemical, Heart Care and Data Stocks

Among the home care ingredient, cardiac care and data science shares on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.

Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.

The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.

Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.

What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.

Why Latent View Analytics Features Among These Biotech Chemical, Heart Care and Data Stocks

Among the three companies on this list, Latent View Analytics, headquartered in Chennai, provides data analytics, engineering and artificial intelligence services to technology, consumer and financial clients worldwide.

The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 4,968 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5.

Revenue rose from Rs 429 crore in FY22 to Rs 1,136 crore in FY26, a compound annual growth rate of 27.6%. Net profit grew from Rs 130 crore in FY22 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 18.8% year on year to Rs 308 crore.

Roadmap: Enterprises are investing in analytics and artificial intelligence, which feeds demand for data services. The company is widening its client list and scaling large accounts with a consulting and engineering model.

What to watch: Follow client additions and the growth of large accounts.

Rossari Biotech vs Narayana Hrudayalaya vs Latent View Analytics on Key Financials

The table below sets the three biotech chemical, heart care and data stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Rossari Biotech 1,495 2,419 12.8% 149 6.2%
Narayana Hrudayalaya 3,736 7,996 21.0% 810 10.1%
Latent View Analytics 429 1,136 27.6% 202 17.8%

Narayana Hrudayalaya posts the highest return on equity in this group at 17.8%. Narayana Hrudayalaya has the largest FY26 revenue at Rs 7,996 crore, and Latent View Analytics shows the fastest revenue growth with a 27.6% compound annual rate. A useful habit with biotech chemical, heart care and data stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Biotech Chemical, Heart Care and Data Stocks

Every theme carries risks that deserve a check before any decision. For these biotech chemical, heart care and data stocks, the main points are: Long-term home care ingredient, cardiac care and data science shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Raw material and energy costs. Input prices can move margins in chemicals.
  • Capacity ramp up. New hospitals take time to fill beds and reach full returns.
  • Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter biotech chemical, heart care and data stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Biotech Chemical, Heart Care and Data Stocks

Biotech chemical, heart care and data stocks work best when investors track growth, valuation and return on equity side by side. Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics each have a clear plan to grow. Based on the 16 November 2026 close, Rossari Biotech trades at Rs 427.15, Narayana Hrudayalaya at Rs 1,895.3 and Latent View Analytics at Rs 201.51.

Download the Univest iOS App or Univest Android App to track biotech chemical, heart care and data stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are biotech chemical, heart care and data stocks?

Ans. Biotech chemical, heart care and data stocks are listed companies that make specialty chemicals for home care, textiles and animal care, run multi speciality hospitals with a focus on heart care, and provide data analytics services to global clients. Their earnings depend on chemical demand, patient volumes and client technology budgets. This list looks at three of them, Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which biotech chemical, heart care and data stocks are covered in this list?

Ans. This list covers Rossari Biotech, Narayana Hrudayalaya and Latent View Analytics. Based on the 16 November 2026 close, Rossari Biotech traded at Rs 427.15, Narayana Hrudayalaya at Rs 1,895.3 and Latent View Analytics at Rs 201.51. Their return on equity ranges from 10.8% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.8% to 27.6%.

Why do biotech chemical, heart care and data stocks have a strong future roadmap in India?

Ans. Biotech chemical, heart care and data stocks have a strong roadmap in India because wider use of specialty chemicals, rising need for affordable specialist care and growing use of data in business decisions keep widening the market for these companies. The main drivers are as follows. Specialty chemicals. Brands need niche formulation inputs. Heart hospitals. Families seek affordable specialist care. Data analytics. Firms use data to decide faster. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Rossari Biotech performed financially?

Ans. Revenue rose from Rs 1,495 crore in FY22 to Rs 2,419 crore in FY26, a compound annual growth rate of 12.8%. Net profit grew from Rs 97.7 crore in FY22 to Rs 149 crore in FY26, which works out to a compound annual growth rate of 11.2%. The company has a return on equity of 10.8%, a debt to equity ratio of 0.28 and a market capitalisation of Rs 2,363 crore. The stock trades at a P/E of 15.5, below the industry P/E of 33.9. Looking ahead, the company is broadening its range across home and personal care, animal nutrition and performance chemicals. Cross-selling to existing customers helps add volume.

How has Narayana Hrudayalaya performed financially?

Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.

How has Latent View Analytics performed financially?

Ans. Revenue rose from Rs 429 crore in FY22 to Rs 1,136 crore in FY26, a compound annual growth rate of 27.6%. Net profit grew from Rs 130 crore in FY22 to Rs 202 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 18.8% year on year to Rs 308 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 4,968 crore. The stock trades at a P/E of 25.0, above the industry P/E of 17.5. Looking ahead, enterprises are investing in analytics and artificial intelligence, which feeds demand for data services. The company is widening its client list and scaling large accounts with a consulting and engineering model.

What risks should investors check before buying biotech chemical, heart care and data stocks?

Ans. Investors should check a few risks before buying biotech chemical, heart care and data stocks. Raw material and energy costs. Input prices can move margins in chemicals. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of biotech chemical, heart care and data stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.



Best Stocks biotech chemical cardiac care and data science shares heart care and data stocks home care ingredient hospitals group and analytics services stocks Latent View Analytics Narayana Hrudayalaya Rossari Biotech specialty chemicals
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply